Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice.

NPJ Vaccines · 2023 · PMC10310740 · PMID 37386041

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These results are highly significant, as MF59 (Addavax equivalent) is the adjuvant currently licensed for use in influenza vaccines for the elderly (Fluad®), and thus highlight the potential for improving vaccine responses in the context of aging with the IN NE/IVT adjuvant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.